Symbols / PCVX Stock $47.41 -3.07% Vaxcyte, Inc.

Healthcare • Biotechnology • United States • NMS
PCVX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Grant E. Pickering M.B.A.
Exch · Country NMS · United States
Market Cap 6.85B
Enterprise Value 5.23B
Income -946.53M
Sales —
FCF (ttm) -439.79M
Book/sh 20.76
Cash/sh 12.03
Employees 507
Insider 10d —
IPO Jun 12, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.39
PEG —
P/S —
P/B 2.28
P/C —
EV/EBITDA -4.87
EV/Sales —
Quick Ratio 7.18
Current Ratio 7.49
Debt/Eq 3.88
LT Debt/Eq —
EPS (ttm) -6.89
EPS next Y -7.42
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA -20.23%
ROE -30.55%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 144.40M
Shs Float 131.96M
Insider Own 0.53%
Instit Own 114.57%
Short Float 9.60%
Short Ratio 9.61
Short Interest 13.79M
52W High 65.00
vs 52W High -27.06%
52W Low 29.08
vs 52W Low 63.03%
Beta 1.30
Impl. Vol. 3.13%
Rel Volume 0.79
Avg Volume 1.41M
Volume 1.11M
Target (mean) $109.00
Tgt Median $110.00
Tgt Low $67.00
Tgt High $163.00
# Analysts 9
Recom Strong_buy
Prev Close $48.91
Price $47.41
Change -3.07%
About

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$109.00
Mean price target
2. Current target
$47.41
Latest analyst target
3. DCF / Fair value
$-54.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$47.41
Low
$67.00
High
$163.00
Mean
$109.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-26 main BTIG Buy → Buy $89
2026-02-02 reit Guggenheim Buy → Buy $116
2025-11-10 reit BTIG Buy → Buy $85
2025-10-16 main BTIG Buy → Buy $85
2025-09-12 init Goldman Sachs — → Neutral $38
2025-04-22 init Cantor Fitzgerald — → Overweight —
2025-04-08 reit Needham Buy → Buy $90
2025-04-01 main Goldman Sachs Buy → Buy $100
2025-04-01 main B of A Securities Buy → Buy $137
2025-04-01 main Needham Buy → Buy $90
2025-03-12 reit Guggenheim Buy → Buy $160
2025-02-26 reit Guggenheim Buy → Buy $160
2025-02-26 reit Needham Buy → Buy $140
2025-02-24 reit BTIG Buy → Buy $160
2025-02-11 reit Needham Buy → Buy $14
2024-12-24 reit BTIG Buy → Buy $160
2024-12-20 init Goldman Sachs — → Buy $135
2024-11-06 reit Cantor Fitzgerald — → Overweight —
2024-11-06 reit Needham Buy → Buy $140
2024-09-10 main Mizuho Outperform → Outperform $163
News
RSS: Latest PCVX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 WASSIL JAMES Chief Operating Officer — 2,250 $56.83 $127,870
2026-04-07 COWAN ELVIA Officer — 3,000 $60.00 $180,000
2026-04-07 COWAN ELVIA Officer — 3,000 $25.92 $77,760
2026-04-01 WASSIL JAMES Chief Operating Officer — 2,250 $58.14 $131,476
2026-03-17 COWAN ELVIA Officer — 1,892 $55.39 $105,147
2026-03-11 COWAN ELVIA Officer — 2,500 $58.59 $146,482
2026-03-11 COWAN ELVIA Officer — 2,500 $25.92 $64,800
2026-03-10 WASSIL JAMES Chief Operating Officer — 7,395 $58.32 $435,440
2026-02-27 WASSIL JAMES Chief Operating Officer — 37,147 $0.00 $314,997
2026-02-26 DHALIWAL HARPREET S. Chief Technology Officer — 53,409 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
923.67
+62.18%
569.55
+44.91%
393.04
+87.82%
209.26
Research And Development
794.31
+66.65%
476.64
+43.42%
332.34
+96.13%
169.45
Selling General And Administration
129.37
+39.25%
92.90
+53.05%
60.70
+52.47%
39.81
General And Administrative Expense
129.37
+39.25%
92.90
+53.05%
60.70
+52.47%
39.81
Other Gand A
129.37
+39.25%
92.90
+53.05%
60.70
+52.47%
39.81
Other Operating Expenses
—
—
-4.76
-146.76%
-1.93
Total Expenses
923.67
+62.18%
569.55
+44.91%
393.04
+87.82%
209.26
Operating Income
-923.67
-62.18%
-569.55
-44.91%
-393.04
-87.82%
-209.26
Total Operating Income As Reported
-923.67
-62.18%
-569.55
-21.69%
-468.04
-101.52%
-232.26
EBITDA
-898.82
-62.33%
-553.70
-44.62%
-382.87
-78.89%
-214.03
Normalized EBITDA
-898.82
-62.33%
-553.70
-79.85%
-307.87
-61.16%
-191.03
Reconciled Depreciation
24.86
+56.89%
15.85
+55.79%
10.17
+7.60%
9.45
EBIT
-923.67
-62.18%
-569.55
-44.91%
-393.04
-75.87%
-223.48
Total Unusual Items
0.00
0.00
+100.00%
-75.00
-226.16%
-23.00
Total Unusual Items Excluding Goodwill
0.00
0.00
+100.00%
-75.00
-226.16%
-23.00
Special Income Charges
0.00
0.00
+100.00%
-75.00
-226.16%
-23.00
Restructuring And Mergern Acquisition
0.00
0.00
-100.00%
75.00
+226.16%
23.00
Net Income
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Pretax Income
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Net Non Operating Interest Income Expense
119.72
+8.84%
109.99
+74.85%
62.91
+653.02%
8.35
Interest Expense Non Operating
—
0.00
0.00
-100.00%
0.00
Net Interest Income
119.72
+8.84%
109.99
+74.85%
62.91
+653.02%
8.35
Interest Expense
—
0.00
0.00
-100.00%
0.00
Interest Income Non Operating
119.72
+8.84%
109.99
+74.85%
62.91
+652.84%
8.36
Interest Income
119.72
+8.84%
109.99
+74.85%
62.91
+652.84%
8.36
Other Income Expense
37.33
+953.23%
-4.38
+93.93%
-72.13
-219.48%
-22.58
Other Non Operating Income Expenses
37.33
+953.23%
-4.38
-252.55%
2.87
+587.77%
0.42
Gain On Sale Of Security
—
—
-1.90
-29.05%
-1.47
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Net Income From Continuing Operation Net Minority Interest
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Net Income From Continuing And Discontinued Operation
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Net Income Continuous Operations
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Normalized Income
-766.63
-65.25%
-463.93
-41.76%
-327.27
-63.23%
-200.49
Net Income Common Stockholders
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Diluted EPS
-5.63
-48.16%
-3.80
+8.21%
-4.14
-20.35%
-3.44
Basic EPS
-5.63
-48.16%
-3.80
+8.21%
-4.14
-20.35%
-3.44
Basic Average Shares
136.09
+11.55%
122.00
+25.57%
97.16
+49.75%
64.88
Diluted Average Shares
136.09
+11.55%
122.00
+25.57%
97.16
+49.75%
64.88
Diluted NI Availto Com Stockholders
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Gain On Sale Of PPE
—
—
0.00
+100.00%
-0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
3,002.72
-14.48%
3,511.32
+149.40%
1,407.92
+39.93%
1,006.18
Current Assets
1,627.36
-8.98%
1,787.98
+63.14%
1,095.95
+16.27%
942.55
Cash Cash Equivalents And Short Term Investments
1,560.96
-10.66%
1,747.21
+61.74%
1,080.23
+15.98%
931.38
Cash And Cash Equivalents
173.96
-55.15%
387.88
-2.41%
397.45
-52.38%
834.66
Cash Equivalents
88.54
-72.95%
327.35
-5.79%
347.45
-55.37%
778.46
Cash Financial
85.42
+41.11%
60.53
+21.05%
50.00
-11.02%
56.20
Other Short Term Investments
1,387.00
+2.04%
1,359.33
+99.09%
682.78
+605.94%
96.72
Prepaid Assets
—
—
—
11.18
Other Current Assets
66.40
+62.84%
40.78
+159.28%
15.73
+40.68%
11.18
Total Non Current Assets
1,375.36
-20.19%
1,723.33
+452.42%
311.96
+390.33%
63.62
Net PPE
491.72
+47.83%
332.62
+128.90%
145.31
+359.15%
31.65
Gross PPE
524.49
+50.33%
348.90
+125.70%
154.58
+309.33%
37.77
Accumulated Depreciation
-32.77
-101.36%
-16.27
-75.52%
-9.27
-51.58%
-6.12
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
338.69
+56.17%
216.87
+144.00%
88.88
+4291.40%
2.02
Construction In Progress
—
—
—
—
Other Properties
178.56
+39.89%
127.64
+98.69%
64.24
+86.81%
34.39
Leases
7.24
+65.12%
4.38
+200.27%
1.46
+7.91%
1.35
Investments And Advances
881.66
-36.46%
1,387.51
+752.93%
162.68
+512.73%
26.55
Non Current Prepaid Assets
—
—
2.77
-36.53%
4.36
Other Non Current Assets
1.97
-38.29%
3.20
-19.56%
3.98
+273.43%
1.06
Total Liabilities Net Minority Interest
317.21
+54.36%
205.50
+22.72%
167.45
+218.56%
52.56
Current Liabilities
205.75
+46.78%
140.18
-3.55%
145.34
+258.64%
40.52
Payables And Accrued Expenses
176.63
+55.30%
113.73
-10.56%
127.17
+280.35%
33.44
Payables
75.61
+55.72%
48.55
+232.86%
14.59
+48.92%
9.79
Accounts Payable
70.90
+46.34%
48.45
+232.16%
14.59
+48.92%
9.79
Current Accrued Expenses
101.02
+54.98%
65.18
-42.10%
112.58
+376.24%
23.64
Pensionand Other Post Retirement Benefit Plans Current
23.00
+11.89%
20.55
+85.92%
11.06
+836.95%
1.18
Total Tax Payable
4.71
+4513.73%
0.10
—
—
Current Debt And Capital Lease Obligation
6.12
+3.96%
5.89
-17.18%
7.11
+20.36%
5.91
Current Capital Lease Obligation
6.12
+3.96%
5.89
-17.18%
7.11
+20.36%
5.91
Current Deferred Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
111.46
+70.63%
65.32
+195.41%
22.11
+83.65%
12.04
Long Term Debt And Capital Lease Obligation
111.36
+70.74%
65.22
+194.96%
22.11
+83.78%
12.03
Long Term Capital Lease Obligation
111.36
+70.74%
65.22
+194.96%
22.11
+83.78%
12.03
Non Current Deferred Liabilities
—
—
—
—
Other Non Current Liabilities
0.10
+0.00%
0.10
—
0.01
Stockholders Equity
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Common Stock Equity
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Capital Stock
0.13
+4.69%
0.13
+30.61%
0.10
+19.51%
0.08
Common Stock
0.13
+4.69%
0.13
+30.61%
0.10
+19.51%
0.08
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
131.06
+4.94%
124.89
+30.96%
95.36
+20.00%
79.47
Ordinary Shares Number
131.06
+4.94%
124.89
+30.96%
95.36
+20.00%
79.47
Additional Paid In Capital
4,838.74
+3.00%
4,697.88
+117.03%
2,164.58
+46.65%
1,476.02
Retained Earnings
-2,154.95
-55.22%
-1,388.32
-50.19%
-924.39
-77.04%
-522.13
Gains Losses Not Affecting Retained Earnings
1.59
+140.98%
-3.87
-2263.69%
0.18
+149.58%
-0.36
Other Equity Adjustments
1.59
+140.98%
-3.87
-2263.69%
0.18
+149.58%
-0.36
Total Equity Gross Minority Interest
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Total Capitalization
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Working Capital
1,421.61
-13.73%
1,647.81
+73.34%
950.62
+5.39%
902.03
Invested Capital
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Total Debt
117.48
+65.21%
71.11
+143.33%
29.22
+62.89%
17.94
Capital Lease Obligations
117.48
+65.21%
71.11
+143.33%
29.22
+62.89%
17.94
Net Tangible Assets
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Tangible Book Value
2,685.51
-18.76%
3,305.82
+166.50%
1,240.47
+30.08%
953.61
Available For Sale Securities
881.66
-36.46%
1,387.51
+752.93%
162.68
—
Investmentin Financial Assets
881.66
-36.46%
1,387.51
+752.93%
162.68
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-655.58
-44.84%
-452.63
-52.51%
-296.79
-73.97%
-170.60
Cash Flow From Continuing Operating Activities
-655.58
-44.84%
-452.63
-52.51%
-296.79
-73.97%
-170.60
Net Income From Continuing Operations
-766.63
-65.25%
-463.93
-15.33%
-402.27
-80.00%
-223.49
Depreciation Amortization Depletion
24.86
+56.89%
15.85
+55.79%
10.17
+7.60%
9.45
Depreciation
24.86
+56.89%
15.85
+55.79%
10.17
+7.60%
9.45
Depreciation And Amortization
24.86
+56.89%
15.85
+55.79%
10.17
+7.60%
9.45
Other Non Cash Items
-14.43
+62.71%
-38.70
-11.30%
-34.77
-593.40%
7.05
Stock Based Compensation
138.84
+63.69%
84.82
+73.96%
48.76
+106.17%
23.65
Asset Impairment Charge
—
—
0.00
-100.00%
0.21
Operating Gains Losses
-34.77
-921.55%
4.23
—
0.04
Net Foreign Currency Exchange Gain Loss
-34.77
-921.55%
4.23
0.00
0.00
Change In Working Capital
-3.45
+93.71%
-54.90
-167.50%
81.32
+538.45%
12.74
Change In Prepaid Assets
-16.80
-188.31%
-5.83
-132.61%
17.87
+4027.02%
0.43
Change In Payables And Accrued Expense
56.93
+337.10%
-24.01
-126.09%
92.02
+562.36%
13.89
Change In Accrued Expense
37.03
+163.19%
-58.60
-172.52%
80.80
+634.71%
11.00
Change In Payable
19.91
-42.44%
34.58
+208.10%
11.22
+287.60%
2.90
Change In Account Payable
19.91
-42.44%
34.58
+208.10%
11.22
+287.60%
2.90
Change In Other Working Capital
2.30
-75.81%
9.52
-3.64%
9.88
+534.11%
-2.27
Change In Other Current Assets
-92.26
-20.66%
-76.46
-53.75%
-49.73
-10594.84%
-0.47
Change In Other Current Liabilities
46.37
+10.71%
41.89
+271.20%
11.28
+880.36%
1.15
Investing Cash Flow
437.35
+121.81%
-2,005.67
-159.36%
-773.31
-1136.82%
74.58
Cash Flow From Continuing Investing Activities
437.35
+121.81%
-2,005.67
-159.36%
-773.31
-1136.82%
74.58
Net PPE Purchase And Sale
-56.97
+52.19%
-119.16
-75.55%
-67.88
-1062.08%
-5.84
Purchase Of PPE
-56.97
+52.19%
-119.16
-75.55%
-67.88
-1062.08%
-5.84
Sale Of PPE
—
—
0.00
-100.00%
0.01
Capital Expenditure
-56.97
+52.19%
-119.16
-75.55%
-67.88
-1062.08%
-5.84
Net Investment Purchase And Sale
494.33
+126.20%
-1,886.51
-167.43%
-705.43
-977.12%
80.43
Purchase Of Investment
-1,211.50
+60.75%
-3,086.70
-132.10%
-1,329.90
-1194.37%
-102.75
Sale Of Investment
1,705.83
+42.13%
1,200.19
+92.20%
624.46
+240.92%
183.17
Financing Cash Flow
2.01
-99.92%
2,448.51
+282.69%
639.81
-25.74%
861.55
Cash Flow From Continuing Financing Activities
2.01
-99.92%
2,448.51
+282.69%
639.81
-25.74%
861.55
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
2,435.66
+282.94%
636.04
-25.74%
856.48
Proceeds From Stock Option Exercised
13.01
-52.09%
27.14
+255.01%
7.65
+28.98%
5.93
Net Other Financing Charges
-10.99
+23.10%
-14.29
-268.73%
-3.88
-350.17%
-0.86
Changes In Cash
-216.21
-2109.60%
-9.79
+97.73%
-430.29
-156.21%
765.53
Effect Of Exchange Rate Changes
2.44
+472.54%
0.43
+106.37%
-6.69
-4980.29%
0.14
Beginning Cash Position
389.19
-2.35%
398.55
-52.30%
835.53
+1096.07%
69.86
End Cash Position
175.43
-54.93%
389.19
-2.35%
398.55
-52.30%
835.53
Free Cash Flow
-712.55
-24.62%
-571.79
-56.80%
-364.67
-106.68%
-176.44
Interest Paid Supplemental Data
—
—
0.00
-100.00%
0.00
Amortization Of Securities
—
—
-34.77
-3572.12%
-0.95
Common Stock Issuance
0.00
-100.00%
2,435.66
+282.94%
636.04
-25.74%
856.48
Issuance Of Capital Stock
0.00
-100.00%
2,435.66
+282.94%
636.04
-25.74%
856.48
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category